As expected, a higher incidence of AEs, particularly diarrhea and stomatitis (42% vs. 20%), as well as of anti-EGFR-related AEs (76% vs. 42%), was found with 5FU/LV+panitumumab compared to that with panitumumab alone (9). This evidence concerns the gene EGFR and stomatitis.